Literature DB >> 35325342

PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.

Liqiang Qi1, Bo Sun2, Beibei Yang2, Su Lu2.   

Abstract

PURPOSE: Triple-negative breast cancer (TNBC) represents an aggressive subtype of breast cancer characteristic of high recurrence rate and poor prognosis. According to previous studies and bioinformatics prediction, PGM5P3-AS1 has been found to be significantly down-regulated in TNBC cells. In addition, cell ferroptosis has become a hotspot in breast cancer research and TNBC has been reported to be more sensitive to ferroptosis than receptor positive breast cancer. Hence, we aim at exploring the molecular mechanism of PGM5P3-AS1 in TNBC cells and further explore whether PGM5P3-AS1 can inhibit TNBC progression via promoting cell ferroptosis.
METHODS: The expression of genes in TNBC cells was verified by RT-qPCR assay. Functional assays were taken to evaluate the impact PGM5P3-AS1 may exert on TNBC progression. The regulatory pattern of PGM5P3-AS1 on cell ferroptosis in TNBC was validated through mechanism assays.
RESULTS: PGM5P3-AS1 was proved to be down-regulated in TNBC cells and suppressed TNBC cell proliferation as well as migration. PGM5P3-AS1 promoted cell ferroptosis in TNBC by recruiting RNA-binding protein (RBP) NOP58 to stabilize MAP1LC3C mRNA, and thus inhibiting TNBC progression.
CONCLUSION: PGM5P3-AS1 regulated MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of TNBC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Ferroptosis; MAP1LC3C; NOP58; PGM5P3-AS1; Triple-negative breast cancer

Mesh:

Substances:

Year:  2022        PMID: 35325342     DOI: 10.1007/s10549-021-06501-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  20 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

Review 2.  Biology and Management of Patients With Triple-Negative Breast Cancer.

Authors:  Priyanka Sharma
Journal:  Oncologist       Date:  2016-07-11

3.  Six genes as potential diagnosis and prognosis biomarkers for hepatocellular carcinoma through data mining.

Authors:  Yaqiong Zhang; Yong Wang; Huaidong Liu; Bo Li
Journal:  J Cell Physiol       Date:  2018-12-17       Impact factor: 6.384

4.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Authors:  Charissa Kim; Ruli Gao; Emi Sei; Rachel Brandt; Johan Hartman; Thomas Hatschek; Nicola Crosetto; Theodoros Foukakis; Nicholas E Navin
Journal:  Cell       Date:  2018-04-19       Impact factor: 41.582

Review 5.  Breast cancer statistics, 2011.

Authors:  Carol DeSantis; Rebecca Siegel; Priti Bandi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-10-03       Impact factor: 508.702

Review 6.  Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.

Authors:  Bin Bao; Ananda S Prasad
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 7.  Triple-negative breast cancer and the potential for targeted therapy.

Authors:  Jing-Ru Jhan; Eran R Andrechek
Journal:  Pharmacogenomics       Date:  2017-11-02       Impact factor: 2.533

Review 8.  Ferroptosis, a new form of cell death: opportunities and challenges in cancer.

Authors:  Yanhua Mou; Jun Wang; Jinchun Wu; Dan He; Chunfang Zhang; Chaojun Duan; Bin Li
Journal:  J Hematol Oncol       Date:  2019-03-29       Impact factor: 17.388

Review 9.  Ferroptosis: past, present and future.

Authors:  Jie Li; Feng Cao; He-Liang Yin; Zi-Jian Huang; Zhi-Tao Lin; Ning Mao; Bei Sun; Gang Wang
Journal:  Cell Death Dis       Date:  2020-02-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.